These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. SARS-CoV-2 positivity in a discharged COVID-19 patient: a case report. Li J; Long X; Fang X; Zhang Q; Hu S; Lin Z; Xiong N Clin Microbiol Infect; 2020 Aug; 26(8):1115-1117. PubMed ID: 32360448 [No Abstract] [Full Text] [Related]
24. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities. Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973 [No Abstract] [Full Text] [Related]
25. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19. Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269 [No Abstract] [Full Text] [Related]
26. Lessons from the Italian COVID-19 frontline. Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392 [No Abstract] [Full Text] [Related]
27. Co-infection of SARS-CoV-2 and HIV in a patient in Wuhan city, China. Zhu F; Cao Y; Xu S; Zhou M J Med Virol; 2020 Jun; 92(6):529-530. PubMed ID: 32160316 [No Abstract] [Full Text] [Related]
28. Storm of soluble immune checkpoints associated with disease severity of COVID-19. Kong Y; Wang Y; Wu X; Han J; Li G; Hua M; Han K; Zhang H; Li A; Zeng H Signal Transduct Target Ther; 2020 Sep; 5(1):192. PubMed ID: 32895366 [No Abstract] [Full Text] [Related]
29. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678 [TBL] [Abstract][Full Text] [Related]
30. Immunosuppression drug advice and COVID-19: are we doing more harm than good? Warraich R; Amani L; Mediwake R; Tahir H Br J Hosp Med (Lond); 2020 Jun; 81(6):1-3. PubMed ID: 32589546 [TBL] [Abstract][Full Text] [Related]
31. The 2019 human coronavirus: Ten areas of uncertainty waiting to be resolved. Mortimer PP Rev Med Virol; 2020 Jul; 30(4):e2114. PubMed ID: 32394505 [No Abstract] [Full Text] [Related]
32. COVID-19 and rheumatology: is shielding really necessary? Amani L; Warraich R; Patel N; Tahir H Br J Hosp Med (Lond); 2020 Jun; 81(6):1-3. PubMed ID: 32589537 [TBL] [Abstract][Full Text] [Related]
33. Cellular immune responses to covid-19. Sewell HF; Agius RM; Stewart M; Kendrick D BMJ; 2020 Jul; 370():m3018. PubMed ID: 32737031 [No Abstract] [Full Text] [Related]
34. Biomarker-guided application of low-dose anakinra in an acute respiratory distress syndrome patient with severe COVID-19 and cytokine release syndrome. Steinhardt MJ; Wiebecke S; Weismann D; Frantz S; Tony HP; Klinker H; Schmalzing M Scand J Rheumatol; 2020 Sep; 49(5):414-416. PubMed ID: 32914670 [No Abstract] [Full Text] [Related]
35. Interleukin-6 and severe COVID-19: a systematic review and meta-analysis. Mojtabavi H; Saghazadeh A; Rezaei N Eur Cytokine Netw; 2020 Jun; 31(2):44-49. PubMed ID: 32933891 [TBL] [Abstract][Full Text] [Related]
36. The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. Buszko M; Park JH; Verthelyi D; Sen R; Young HA; Rosenberg AS Nat Immunol; 2020 Oct; 21(10):1146-1151. PubMed ID: 32855555 [No Abstract] [Full Text] [Related]
38. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. DiNicolantonio JJ; Barroso J; McCarty M Open Heart; 2020 Sep; 7(2):. PubMed ID: 32895293 [No Abstract] [Full Text] [Related]
39. Clinical characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China. Chu J; Yang N; Wei Y; Yue H; Zhang F; Zhao J; He L; Sheng G; Chen P; Li G; Wu S; Zhang B; Zhang S; Wang C; Miao X; Li J; Liu W; Zhang H J Med Virol; 2020 Jul; 92(7):807-813. PubMed ID: 32222986 [TBL] [Abstract][Full Text] [Related]
40. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. La Rosée F; Bremer HC; Gehrke I; Kehr A; Hochhaus A; Birndt S; Fellhauer M; Henkes M; Kumle B; Russo SG; La Rosée P Leukemia; 2020 Jul; 34(7):1805-1815. PubMed ID: 32518419 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]